Haemonetics ($HAE) lowered its 2016 guidance, citi

Haemonetics ($HAE) lowered its 2016 guidance, citing deterioration in the market for its products in Russia, challenges in the pace of implementation of a contracted market share gain in Japan and re-assessment of the timeline for penetration of recently introduced software products. The company’s second quarter earnings guidance is above estimates, while its revenue outlook trailed expectations.